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1. Introduction
Atrial  fibrillation (AF)  is  the  most  common cardiac  arrhythmia,  affecting approximately
1% of the general population and up to 8% of subjects over the age of 80 years.[1] AF is
a major contributor to cardiovascular mortality and morbidity, being associated with de‐
creased  quality  of  life,  increased  incidence  of  congestive  heart  failure,[2]  embolic  phe‐
nomena,  including  stroke,[2,3]  and  a  30  %  higher  risk  of  death.[3,4]  AF-associated
morbidity  includes  a  four-  to  five-fold  increased  risk  for  stroke,  [2,5]  a  two-fold  in‐
creased risk for dementia,[6,7] and a tripling of risk for heart failure.[5] According to the
Framingham Study,  the  percentage  of  strokes  attributable  to  AF increases  steeply  from
1.5% at 50–59 years of age to 23.5% at 80–89 years of age, [2] and the presence of AF ac‐
counts  for  a  50–90%  increased  risk  for  overall  mortality.[3]  From  the  viewpoint  of  the
AF-related  socio-economic  burden,  it  has  been  estimated  that  it  is  consuming  between
0.9% and 2.4% of  total  National  Health  Service  expenditure  in  the  UK,[8]  while  in  the
USA,  total  costs  are  8.6–22.6%  higher  for  AF  patients  in  all  age-  and  sex-  population
strata.[9]  Therefore  significant  clinical,  human,  social  and economical  benefits  are  there‐
fore expected from any improvement in AF prevention and treatment.
It has to be noted that although multiple treatment options are currently available, no single
modality is effective for all patients.[10] AF can occasionally affect a structurally normal
heart of otherwise healthy individuals (so-called “lone AF”)[11], but most typically it occurs
in subjects with previous cardiovascular damage due to hypertension, coronary artery dis‐
ease and diabetes. Moreover, it can be associated with clinical conditions such as hyperthyr‐
oidism, acute infections, recent cardiothoracic or abdominal surgery, and systemic
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inflammatory diseases. Whatever the cause, AF is characterized by very rapid, chaotic elec‐
trical activity of the atria, resulting in accelerated and irregular ventricular activity, loss of
atrial mechanical function and increased risk of atrial clot formation.
Many studies have shown that the recurrence of AF may be partially related to a phenomen‐
on known as “atrial remodeling”, in which the electrical, mechanical, and structural proper‐
ties of the atrial tissue and cardiac cells are progressively altered, creating a more favorable
substrate for AF development and maintenance.[12,13] Atrial remodeling is both a cause
and a consequence of the arrhythmia, and in recent years it has become more and more evi‐
dent that treatment should also be based on an “upstream” therapy[14,10] aimed at modify‐
ing the arrhythmia substrate and at reducing the extent of atrial remodelling.
2. Atrial remodeling: electrical and structural factors
According to  Coumel´s  triangle  of  arrhythmogenesis,  three  cornerstones  are  required in
the  onset  of  clinical  arrhythmia[15]  –  the  arrhythmogenic  substrate,  the  trigger  factor
and the modulation factors such as autonomic nervous system or inflammation. Once es‐
tablished,  AF  itself  alters  electrical  and  subsequently  structural  properties  of  the  atrial
tissue  and these  changes  cause  or  “beget”  further  AF self-perpetuation.[12]  The mecha‐
nisms  responsible  for  the  onset  and  persistence  of  the  arrhythmia  involve  electrical  as
well as structural determinants, that are very complex and yet poorly understood. From
the electrical standpoint,  there is still  debate on the three models that were proposed in
1924[16]  by  Garrey  for  describing  the  mechanisms  of  spatiotemporal  organization  of
electrical  activity  in  the  atria  during AF.  According to  the  focal  mechanism theory,  AF is
provoked and perhaps also driven further by the rapid firing of a single or multiple ec‐
topic foci, whereas the single circuit re-entry theory assumes the presence of a single dom‐
inant re-entry circuit,  and the multiple  wavelet  theory  postulates the existence of  multiple
reentry  circuits  with  randomly  propagating  wave-fronts  that  must  find  receptive  tissue
in  order  to  persist.[17]  It  has  to  be  recognized  that  all  three  models  are  non-exclusive
and each may be applicable to certain subgroups of AF patients,  or that they may even
coexist  in  the  same  subject  during  different  stages  of  AF  development.  Moreover,  AF
persistence  is  associated  with  modifications  in  the  atrial  myocyte  electrical  properties
(the  so-called  electrical  remodeling),  that  may  stabilize  the  arrhythmia  by  decreasing  the
circuit size.  The electrophysiological properties of the atrial  myocardium may be further
modified  by  changes  in  autonomic  nervous  system  activity  as  well  as  by  the  interfer‐
ence of drugs and hormones, that may therefore participate in arrhythmogenesis.
Beyond these electrical determinants, AF onset and persistence may be affected by the struc‐
tural factors, such as the dimensions and geometry of the atrial chambers, the atrial tissue
structure and the amount and the composition of the extracellular matrix surrounding the
atrial myocytes (i.e. structural remodeling). Together, these alterations create an arrhythmo‐
genic substrate essential for the persistence of AF. Atrial structure is modified by volume
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and pressure overload, due to either mitral valve disease or left ventricular diastolic dys‐
function in the setting of arterial hypertension, coronary artery disease or aortic valve dis‐
ease. Also diabetes is associated with changes in atrial structure and function. It is not
therefore surprising that all these clinical conditions are associated with an increased AF in‐
cidence and prevalence. Beyond being a possible substrate for AF onset, atrial structure is
profoundly altered by the effects of rapid atrial rate. Prolonged rapid atrial pacing induces
changes in atrial myocytes such as an increase in cell-size, myocyte lysis, perinuclear accu‐
mulation of glycogen, alterations in connexin expression, fragmentation of sarcoplasmic re‐
ticulum and changes in mitochondrial shape.[18] Moreover, structural remodeling is
characterized by changes in extracellular matrix composition, with both diffuse interstitial
and patchy fibrosis.[19] All these alterations results in electrical tissue non-homogeneity,
slowed conduction and electrical uncoupling, that facilitate AF continuation. In contrast to
electrical remodeling, structural changes are far less reversible and they tend to persist even
after sinus rhythm restoration. Among the several mechanisms and signaling pathways in‐
volved in structural remodeling and atrial fibrosis, a key role is played by the renin-angio‐
tensin system, and by the transforming growth-factor β1 (TGF-β1) pathway, associated with
tissue inflammation[19] and reactive oxygen species production.[20,21]
Profibrotic signals act on the balance between matrix metalloproteinases (MMPs) – the main
enzymes responsible for extracellular matrix degradation – and their local tissue inhibitors
(TIMPs), that can be differentially altered in compensated as opposed to decompensated
pressure-overload hypertrophy.[22-25] Furthermore, profibrotic signals stimulate the prolif‐
eration of fibroblasts and extracellular deposition of fibronectin, collagens I and III, prote‐
glycans and other matrix components. In a canine model of congestive heart failure, Li et al.
showed that the development of atrial fibrosis is angiotensin-II dependent,[26] via mecha‐
nisms that are partly mediated by the local production of cytokine TGF-β1.[27] In transgenic
mice, overexpression of the latter cytokine has been shown to lead to selective atrial fibrosis,
increased conduction heterogeneity and enhanced AF susceptibility, despite normal atrial
action potential duration and normal ventricular structure and function.[28]
3. The renin-angiotensin-aldosterone system (RAAS) as a “novel” risk
factor for AF
Among many others, two factors contribute to the search of different therapeutic ap‐
proaches to AF specifically targeting substrate development and maintenance:[29] the recog‐
nition of novel risk factors for the development of this arrhythmia and the well-known
limitations of the current antiarrhythmic drug therapy to maintain sinus rhythm, still having
inadequate efficacy and potentially serious adverse effects.[30] In this setting, the inhibition
of the renin-angiotensin-aldosterone system (RAAS) has been considered useful in both pri‐
mary and secondary prevention of AF, particularly in patients presenting left ventricular
hypertrophy (LVH) or heart failure. The RAAS is a major endocrine/paracrine system in‐
volved in the regulation of the cardiovascular system.[31] Its key mediator is angiotensin II,
an octapeptide that is cleaved from the liver-derived 485-aminoacid precursor angiotensino‐
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gen through a process involving the enzymatic activities of renin and angiotensin convert‐
ing enzyme (ACE). Two main angiotensin II receptors exist, i.e angiotensin II type 1 (AT1)
and type 2 (AT2). AT1-receptor mediated pathways lead to vasoconstriction, water retention,
increased renal tubular sodium reabsorption, stimulation of cell growth and connective tis‐
sue deposition, and impaired endothelial function. AT2-receptor has opposing effects, inas‐
much as it mediates vasodilation, decreases renal tubular sodium reabsorption, inhibits cell
growth and connective tissue deposition, and improves endothelial function. These two an‐
giotensin receptors have different expression patterns, AT1 being constitutively expressed in
a wide range of tissues of the cardiovascular, renal, endocrine, and nervous system, and AT2
expression being activated during stress conditions.[32] It is becoming increasingly evident
that all these mechanisms are involved in atrial remodeling and hence in AF development
and maintenance. Moreover, among the other biologically active RAAS components that are
involved in these processes, angiotensin-(1-7) [Ang-(1-7)] seems to be particularly impor‐
tant. In an experimental canine model of chronic atrial pacing, Ang-(1-7) has been shown to
reduce AF vulnerability and atrial fibrosis,[33] influencing atrial tachycardia-induced atrial
ionic remodeling. [34]
Among the compounds that may interfere RAAS four classes of drugs are particularly rele‐
vant in cardiovascular therapy: angiotensin receptor blockers (ARBs), ACE inhibitors
(ACEIs), aldosterone antagonists and direct renin inhibitors. ARBs directly block AT1 recep‐
tor activation, ACEIs inhibit ACE-mediated production of angiotensin II, and the recently
developed direct renin inhibitor aliskiren blocks RAAS further upstream.[32,35,36] Over the
last decade, these drugs have been tested in the setting of AF treatment and prevention.
4. The role of RAAS in the pathogenesis of AF
4.1. Atrial stretch and AF
Atrial arrhythmias frequently occur under conditions associated with atrial dilatation and
increased atrial pressure, causing atrial tissue stretch and modifying atrial refractoriness,
and it has been shown in several animal as well as clinical models.[37-40] These factors in‐
crease susceptibility to AF, that is associated with shortening of the atrial effective refractory
period (AERP), possibly by opening of stretch-activated ion channels. In the setting of arteri‐
al hypertension and congestive heart failure (CHF), angiotensin II has been associated with
increased left atrial and left ventricular end-diastolic pressure,[41] and both ACEIs and
ARBs have been shown to reduce left atrial pressure.[42-45] Therefore, one potential mecha‐
nism by which ACEIs and ARBs may reduce atrial susceptibility to AF is by reducing atrial
stretch. Many other mechanisms appear to be involved in the antiarrhythmic properties of
RAAS inhibition, and in an animal model of ventricular tachycardia-induced CHF it has
been shown that ACE inhibition is more successful than hydralazine/isosorbide mononitrate
association in reducing burst pacing-induced AF promotion, despite a similar reduction in
left atrial pressure.[26] As described below, angiotensin II-mediated mechanisms contribute
to both structural and electrical remodeling of the atrial tissue.
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4.2. The role of RAAS in structural remodeling
Atrial fibrosis causes conduction heterogeneity, hence playing a key role in the development
of a vulnerable structural substrate for AF, and the proinflammatory and profibrotic effects
of angiotensin II have been extensively described.[46-48] Excessive fibrillar collagen deposi‐
tion, resulting from deregulated extracellular matrix metabolism, leads to atrial fibrosis, and
it has been shown that angiotensin II has a direct effect in stimulating cardiac fibroblast pro‐
liferation and collagen synthesis, via AT1 receptor – mediated mechanisms involving a mito‐
gen-activated protein kinases (MAPKs) phosphorylation pathway. [49-51] The latter cascade
is inhibited by AT2 receptor activation, that has an antiproliferative effects.[52] Moreover,
cardiac fibroblast function is modulated by angiotensin II through mechanisms involving
TGF-฀1, osteopontin (OPN), and endothelin-1 (ET-1). [49,53-55] Interestingly, Nakajima and
coworkers showed that selective atrial fibrosis, conduction heterogeneity, and AF propensi‐
ty are enhanced in a TGFβ1 cardiac overexpression transgenic mice model,[56] as also con‐
firmed by others.[27,28]
Beyond having both direct and indirect effects on collagen synthesis, angiotensin II inter‐
feres with collagen degradation by modulating interstitial matrix metalloproteinase (MMP)
activity and tissue inhibitor of metalloproteinase (TIMP) concentrations,[52] and an atrial
tissue imbalance between MMPs and TIMPs has been reported in both clinical and animal
studies on AF. [52,57] Goette and coworkers showed increased atrial expression of ACE and
increased activation of the angiotensin II-related intracellular signal transduction pathway
in human atrial tissue derived from AF patients,[58] and atrial overexpression of angioten‐
sin II has also been shown in a canine model of ventricular tachycardia-induced CHF[26,59]
In transgenic mice experiments with cardiac-restricted ACE overexpression, Xiao et al. have
demonstrated that elevated atrial tissue angiotensin II concentrations stimulates atrial fibro‐
sis and hence an AF-promoting substrate.[60] In contrast, RAAS inhibition reduces tissue
angiotensin II concentration, and attenuates atrial structural remodeling and fibrosis, there‐
by contrasting AF maintenance.[26,59,61-64]
4.3. The role of RAAS in electrical remodeling
Electrical remodeling has been hypothesized as a main mechanism by which, once estab‐
lished,  “AF  begets  further  AF”  self-perpetuation.[12]  In  the  clinical  practice,  this  phe‐
nomenon is evident when considering that over time it becomes more and more difficult
to  keep  in  sinus  rhythm  a  patient  with  AF.  The  concept  of  electrical  remodeling  has
been  originally  proposed  by  Wijffels  et  al.[12]  to  explain  the  experimental  observation
that when AF is maintained artificially, the duration of burst pacing-induced paroxysms
progressively  increases  until  AF  becomes  sustained.  This  indicates  that  AF  itself  alters
the atrial  tissue electrical  properties,  thereby developing a functional  substrate that  pro‐
motes AF perpetuation and may involve alterations in ionic  currents  and in excitability
cellular properties.[65] In their study, Wijffels et al. demonstrated that the increased pro‐
pensity  to  AF  is  associated  with  shortening  of  the  atrial  effective  refractory  period
(AERP) in accordance with the multiple wavelet  theory,[12]  a mechanism that  was sub‐
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sequently  attributed to  a  reduction of  action potential  duration (APD) secondary to  the
progressive downregulation of the transient outward current (Ito)  and of the L-typeCa2+
current (ICa,L).[66] As to the modulation of the ICa,L current,  the role of angiotensin II
is  controversial,  with  studies  reporting  increase,  decrease,  or  even  no  effect.[29,67]  In
contrast,  angiotensin  II  has  been demonstrated to  downregulate  Ito  current,[68,67]  inas‐
much  as  AT1  receptor  stimulation  leads  to  internalization  of  the  Kv4.3  (i.e.,  the  pore-
forming  α-subunit  underlying  Ito),  regulating  its  cell-surface  expression.[68]  As  shown
by Liu  and coworkers,  chronic  Ang-(1-7)  infusion  prevented  the  decrease  of  Ito,  ICa,L,
and of Kv4.3 mRNA expression induced by chronic atrial  pacing, [34] thereby contribu‐
ting  to  reduce  AF  vulnerability.[33]  Subsequently,  Nakashima  et  al.  showed  that  ACEI
or ARB treatment results  in complete inhibition of  the shortening of  AERP, that  is  nor‐
mally induced by rapid atrial pacing.[69] A further mechanism by which the RAAS may
exert  a  proarrhythmic  effect  is  the  modulation  of  gap junctions,  that  are  low-resistance
pathways for the propagation of impulses between cardiomyocytes formed by connexins
(Cx).[70]  Cx40 gene polymorphisms have been associated with  the  development  of  non
familial  AF,[71]  and angiotensin II  has  been implicated in Cx43 downward remodeling.
[72-74] Moreover, angiotensin II directly induces delayed after-depolarizations and accel‐
erates  the automatic  rhythm of  isolated pulmonary vein cardiomyocytes.[75]  These cells
are considered an important source of ectopic beats and of atrial  fibrillation bursts,  rep‐
resenting  the  target  of  AF  treatment  with  radio-frequency  ablation.[76]  Therefore  these
experimental  results  demonstrate that  angiotensin II  may play a role in the pathophysi‐
ology of  atrial  fibrillation also  by modulating the  pulmonary vein  electrical  activity  via
an  electrophysiological  effect  that  was  shown to  be  AT1  receptor  –  mediated,  being  in‐
hibited by losartan, [75] and that is attenuated by heat-stress responses.[77] Recently, al‐
so  the  direct  renin inhibitor  aliskiren was shown to  reduce the  arrhythmogenic  activity
of  pulmonary  vein  cardiomyocytes.[36]  It  has  also  been  demonstrated  that  aldosterone
promotes atrial fibrillation, causing a substrate for atrial arrhythmias characterized by at‐
rial fibrosis,  myocyte hypertrophy, and conduction disturbances,[78] and the specific an‐
tagonist  spironolactone  has  been  shown  to  prevent  aldosterone-induced  increased
duration of atrial fibrillation in a rat model.[79]
4.4. RAAS gene polymorphisms and AF
The ACE DD (deletion/deletion) genotype of the ACE gene has been shown to be a predis‐
posing factor for persistent AF,[80] and it was recently reported that the same genotype is
associated with lowest rates of symptomatic response in patients with lone AF.[81] More‐
over, polymorphisms of the angiotensinogen gene have also been associated with nonfami‐
lial AF,[82] and it has been shown that significant interactions exist between
angiotensinogen gene haplotypes and ACE I/D (insertion/deletion) polymorphism resulting
in increased susceptibility to AF.[83,84] Also aldosterone synthase (CYP11B2) T-344C poly‐
morphism, which is associated with increased aldosterone activity, was shown to be an in‐
dependent predictor of AF in patients with HF.[85] According to Sun and coworkers, this
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aldosterone synthase gene polymorphism might also be associated with atrial remodelling
in hypertensive patients.[86]
5. Atrial fibrillation and the renin-angiotensin-aldosterone system
(RAAS): Clinical observations
A possible  relationship between the  RAAS and the  risk  of  developing AF was brought
about  by several  clinical  data,  derived from patient  series  in  different  settings,  that  are
here summarized.
5.1. Heart failure
In heart  failure,  several  observations indicate a possible effect  of  RAAS inhibition in re‐
ducing  the  incidence  of  new  onset  AF.  In  a  retrospective  analysis  of  the  SOLVD  trial,
Vermes et al. showed that enalapril reduces the risk of AF development in patients with
various degrees  of  heart  failure.[87]  Similarly,  Maggioni  et  al.  demonstrated that  use  of
the ARB valsartan is associated with a reduction in the risk of AF in the Val-HeFT trial
population.[88]  Since  the  vast  majority  of  these  patients  (92.5%)  were  already receiving
an ACEI, a combination effect was hypothesized, and the benefit of combined treatment
with both an ARB and an ACEI was also supported by the results of the CHARM trial
with  candesartan.[89]  The  latter  study  was  composed  by  three  component  trials  based
on left ventricular ejection fraction (LVEF) and ACEI treatment. CHARM-Alternative tri‐
al  enrolled  patients  with  LVEF  ≤40%  not  treated  with  ACEIs  because  of  prior  intoler‐
ance, CHARM-Added recruited patients with LVEF ≤40% already treated with an ACEI,
and CHARM-Preserved included patients  with  LVEF >40%,  independent  of  ACEI treat‐
ment. The incidence of new-onset AF was reduced in candesartan-treated patients, espe‐
cially  (but  not  exclusively)  in  the  CHARM-Alternative  trial.[89]  These  data  indicate
additional  benefits  in  AF  prevention,  on  the  top  of  the  already  known  effects  of
ACEI/ARB treatment in patients with heart failure.
5.2. Post-MI
After an acute myocardial infarction, treatment with the ACEI trandolapril reduced the inci‐
dence AF in patients with impaired left ventricular function, irrespective of the effects on
ejection fraction per se.[90] Similar results were reported by Pizzetti et al. with lisinopril in
their analysis of the GISSI-3 trial.[91]
5.3. Hypertension
The issue of the possible role of ACEI/ARB drug treatment in the primary prevention of
AF in  hypertensive  patients  derives  from several  conflicting  observations.  According to
the  CAPPP  and  the  STOP-H2  trials,  ACEIs  were  comparable  to  other  antihypertensive
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regiments in preventing AF.[92,93] In contrast, a retrospective, longitudinal, cohort study
by L’Allier et  al.  reported a benefit  of  ACEIs over calcium channel blockers in terms of
new onset AF and AF-related hospitalizations.[94] Similar results were derived from the
LIFE trial,  showing that  when compared with  the  β-blocker  atenolol,  patients  receiving
the  ARB  losartan  had  significantly  lower  incidence  of  new-onset  AF  and  associated
stroke.[95] A recent nested case-control observational study showed that compared with
treatment  with  calcium  channel  blockers,  long-term  antihypertensive  treatment  with
ACEIs, ARBs, or β-blockers may decrease the risk of new-onset AF.[96]
5.4. Increased cardiovascular risk
In patients with increased cardiovascular risk, the rate of new onset AF was not reduced by
ramipril in a subanalysis of the HOPE clinical trial by Salehian and coworkers,[97] although
in a population with a rather low incidence of AF (2.1%). Also in the ACTIVE I trial, there
was no benefit of irbesartan treatment in preventing hospitalization for atrial fibrillation or
atrial fibrillation recorded by 12-lead electrocardiography, nor was there a benefit in a sub‐
group of patients who underwent transtelephonic monitoring.[98] In contrast, according to
Schmieder et al. the VALUE trial showed that valsartan-based antihypertensive treatment
reduced the development of new-onset AF compared to amlodipine,[99] in subjects at high‐
er risk of this arrhythmia due to an almost 25% prevalence of electrocardiographically-de‐
fined left ventricular hypertrophy. These conflicting data may indicate that a possible
benefit of ACEI or ARB treatment can at best be observed in patients with the highest proba‐
bility of increased RAAS activation.
5.5. Postoperative AF
A reduced incidence of new-onset AF was observed in patients undergoing coronary artery
bypass graft surgery who were treated with ACEIs,[100] in a large multicenter prospective
trial recruiting 4,657 subjects. These results were confirmed with the use of ACEIs alone or
associated with candesartan,[101] whereas the reduced risk of developing postoperative AF
did not reach the statistical significance in the post hoc evaluation of patients enrolled in the
AFIST II and III trials.[102]
5.6. Secondary prevention after cardioversion and after catheter ablation
In the setting of secondary prevention, patients undergoing AF cardioversion represent a
group in which the potential  role of RAAS inhibition has been first  investigated by van
den Berg et al.[103], iwho studied 30 CHF patients treated with lisinopril or placebo be‐
fore and after  the procedure.  Although the reduced incidence of  recurrent  AF in ACE-I
treated  patients  did  not  reach  the  statistical  significance,  this  study  was  followed  by
many others. Dagres et al.  [104] demonstrated that treatment with the ARB irbesartan is
associated  with  attenuated  left  atrial  stunning  after  cardioversion.  Subsequent  studies
showed that the association of an ACEI or an ARB with amiodarone prevents AF recur‐
rences after cardioversion when compared with amiodarone alone.[105-107] Interestingly,
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irbesartan  showed a  dose-dependent  preventive  effect.[106]  In  contrast,  Tveit  and  cow‐
orkers did not find any benefit  by treating with the ARB candesartan for 3-6 weeks be‐
fore  and  6  months  after  electrical  cardioversion.[108]  We  contributed  to  this  debate  by
showing that also in the setting of lone AF,[11] long-term treatment with the ACE-I ram‐
ipril  is  effective  in  preventing  relapses  of  AF  after  successful  cardioversion.[109]  More‐
over,  at  the  end  of  a  3-year  follow-up,  ramipril  treatment  also  prevented  left  atrium
enlargement,[109]  which  has  been  demonstrated  to  occur  in  the  natural  history  of  lone
AF.[110]
In patients undergoing catheter ablation for drug refractory AF, ACEIs or ARBs did not
show the same promising results,[111-115] raising the question whether these interventions
are indeed able to revert atrial remodeling in this clinical setting.[116]
5.7. Paroxysmal AF prevention
Both  ACEIs  and  ARBs  have  shown  some  promise  in  the  setting  of  the  prevention  of
paroxysmal  AF  recurrences.  In  two  long-term  clinical  trials  on  amiodarone-treated  pa‐
tients,  losartan  or  perindopril  were  more  effective  than  amlodipine  in  the  maintenance
of sinus rhythm. [117,118] The same held true for telmisartan, that Fogari et  al.  showed
as more effective than ramipril in reducing AF recurrence and severity as well as in im‐
proving P-wave dispersion,  suggesting  a  possible  specific  effect  of  telmisartan  on atrial
electric  remodeling.[119]  In a  retrospective analysis  of  patients  with predominantly par‐
oxysmal  AF,  Komatsu  and  coworkers  showed  that  the  enalapril  added  to  amiodarone
reduced the rate of AF recurrence and prevented the development of atrial structural re‐
modeling.[120]  In  a  post  hoc  subgroup  analysis  of  the  AFFIRM  trial,  Murray  et  al.
showed that ACEIs and ARBs reduced the risk of AF recurrence in patients with a his‐
tory of CHF or impaired left ventricular function. [121] The GISSI-AF trial did not show
any significant effect of valsartan treatment on the rate of AF recurrences in a cohort of
1,442 patients with a history of recent AF.[122] Although it  has to be noted that valsar‐
tan-treated patients had a significantly higher prevalence of coronary artery disease and
peripheral  artery  disease,  and  that  more  than  half  of  the  patients  were  already  taking
concomitant  ACEI  treatment,  the  GISSI-AF shed some doubt  on the  whole  issue  of  the
preventive role of RAAS inhibition in AF prevention.[122] In the same line, the very re‐
cent  ANTIPAF  trial  concluded  that  12-month  treatment  with  the  ARB  olmesartan  did
not  reduce  the  number  of  AF  episodes  in  patients  with  documented  paroxysmal  AF
without  structural  heart  disease.[123]  Similar  results  were  shown  by  the  J-RHYTHM  II
study  comparing  the  ARB  candesartan  with  the  calcium  antagonist  amlodipine  in  the
treatment  of  paroxysmal  AF associated with  hypertension.[124]  Both  studies  used daily
transtelephonic  monitoring  to  examine  asymptomatic  and  symptomatic  paroxysmal  AF
episodes. [123,124]
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5.8. Emerging role for aldosterone antagonists
In the recent years, it has been suggested that upstream therapy using aldosterone antago‐
nists, such as spironolactone or eplerenone, may reduce the deleterious effect of excessive
aldosterone secretion on atrial tissue, thereby contributing to modify the risk of developing
and of maintaining AF.[125] Dabrowski et al. showed that combined spironolactone plus be‐
ta-blocker treatment might be a simple and valuable option in preventing AF episodes in pa‐
tients with normal left ventricular function and history of refractory paroxysmal AF.[126] In
patients with AF, spironolactone treatment was associated with a reduction in the AF bur‐
den, as reflected by a combination of hospitalizations for AF and electrical cardioversion.
[127] In a recent trial in patients with systolic heart failure and mild symptoms (EMPHASIS-
HF), the aldosterone antagonist eplerenone reduced the incidence of new-onset AF or atrial
flutter.[128]
5.9. Meta-analyses
The promise of a protective role of RAAS inhibition is largely based on the analysis of retro‐
spective data, although on several thousands of patients. Another limitation is the fact that
in most cases, the detection of AF recurrences is based on annual electrocardiograms, peri‐
odical 24-hour Holter analysis, or patient self-reported symptoms symptoms. In recent
years, with the analysis of data from patients with an implanted pacemaker, it is becoming
increasingly clear that continuous monitoring is much more reliable in identifying the pres‐
ence of asymptomatic recurrences, with a mean sensitivity in detecting an AF episode last‐
ing >5 minutes that was 44.4%, 50.4%, and 65.1% for 24-hour Holter, 1-week Holter, and 1-
month Holter monitoring, respectively.[129] To partially overcome some of these
limitations, several meta-analyses of the available trials have been conducted.[130-141] In
synthesis, despite the promising preliminary experimental and clinical data, the efficacy of
RAAS inhibition in the prevention of atrial fibrillation recurrences is still under debate, lead‐
ing Disertori et al. in a very recent review article to the definition of “an unfulfilled hope”.
[136] In meta-analysis including 92,817 randomized patients, Khatib and coworkers con‐
cluded that although RAAS inhibition appears to reduce the risk of developing new onset
atrial fibrillation in different patient groups, further research with stronger quality trials is
required to draw definitive conclusions.[141]
Indeed, ACE-I or ARBs cannot be considered as an alternative to the established antiar‐
rhythmic  agents  and  transcatheter  ablation.  However,  since  they  are  recommended  for
most  concomitant  cardiovascular  diseases  that  are  associated  with  an  increased  risk  of
AF (i.e.,  hypertension,  heart  failure,  ischemic  heart  disease)  and  since  there  are  several
lines of evidence that increased angiotensin II tissue levels are involved in both structur‐
al and electrical remodeling of the atrial tissue, it appears reasonable to use these drugs.
In  general,  no  substantial  difference  was  found  in  the  comparison  between  ACE-I  and
ARB treatment,  a finding that was confirmed also by the results of the the ONTARGET
and TRANSCEND trials.[142]
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5.10. Atrial remodeling as a therapeutic target: modulation of the renin-angiotensin-
aldosterone system
Since angiotensin II  plays  a  central  role  in  the  development  of  atrial  fibrosis,  inhibition
of  atrial  angiotensin  converting  enzyme (ACE)  and AT1  angiotensin  receptors  might  be
beneficial  in  AF.  In  experimental  models,  AF  susceptibility  and  atrial  fibrosis  were  de‐
creased  by  candesartan  or  enalapril,  but  not  by  hydralazine  or  isosorbide  mononitrate
despite similar hemodynamic effects,[26,63] thus suggesting a key role of targeting renin-
angiotensin system, rather than of  improving the hemodynamics.  This  concept  was fur‐
ther underscored after demonstrating a preventive role of  ramipril  treatment in patients
with lone AF.[109] Also spironolactone was able to prevent AF episodes in patients with
normal  left  ventricular  function  and  a  history  of  refractory  paroxysmal  AF.[126]  With
the notable exception of the GISSI-AF,[122] ANTIPAF,[123] and J-RHYTHM II[124] trials,
the majority of the available studies showed that modulation of the renin-angiotensin-al‐
dosterone  system is  able  to  reduce  the  incidence  of  AF,  as  well  as  its  recurrence  after
electrical  cardioversion.[134]  These  data  are  summarized  in  several  meta-analyses,
[131,132,140,143]  also  including  the  GISSI-AF  data.[135]  In  a  broader  view,  although
ACE inhibitors and angiotensin-II  receptor blockers (ARBs) are not to be considered an‐
tiarrhythmic drugs, several studies have shown that they are associated with a lower in‐
cidence  of  ventricular  arrhythmias  in  patients  with  ischemic  heart  disease  and  left
ventricular (LV) dysfunction,[90,144,145] possibly because of the adverse effects of angio‐
tensin  II  on  the  cardiac  remodeling  process.  Indeed,  it  must  be  recognized  that  in  the
presence  of  a  cardiac  disease  causing  atrial  overload  and/or  dysfunction,  the  effective‐
ness of ACE inhibitors and/or ARBs might be attributable either to a direct antiarrhyth‐
mic  effect  or  to  an  effect  on  atrial  structure  and/or  function  likely  able  to  favorably
modify the arrhythmic substrate,  such as the increase in left  atrial  (LA) dimensions that
is frequently observed in patients with arterial hypertension and/or LV dysfunction.
In the setting of AF, it has to be remembered that angiotensin II not only has several effects
on the structure of the atrial myocardium, but also on its electrical properties, as it has been
elegantly shown in isolated pulmonary vein cardiomyocytes,[75] and in instrumented ani‐
mal studies.[69] Therefore, the protective effect of ACE inhibition or angiotensin II antago‐
nists on the electrical and structural remodeling of the atria is very likely, due to a
combination of their actions on atrial distension/stretch, sympathetic tone, local renin-angio‐
tensin system, electrolyte concentrations, and cardiac loading conditions.
6. Conclusions
The onset of atrial fibrillation results from a complex interaction between triggers, arrhyth‐
mogenic substrate, and modulator factors. Once established, AF itself alters the electrical
and structural properties of the atrial myocardium, thereby perpetuating the arrhythmia.
Among many other factors, angiotensin II and aldosterone play an important role not only
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in determining atrial fibrosis, but also in modulating the electrical properties of the atrial
myocardium. These aspects may be relevant in explaining the many clinical observations in‐
dicating the role of drugs modulating the renin-angiotensin-aldosterone system in prevent‐
ing atrial fibrillation in different settings.
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